Investigating how genetic differences relate to the risk of maternal fever due to epidural pain relief in mothers during labour

ISRCTN ISRCTN99641204
DOI https://doi.org/10.1186/ISRCTN99641204
IRAS number 270480
Secondary identifying numbers IRAS 270480, version 1.0
Submission date
26/04/2021
Registration date
29/04/2021
Last edited
09/06/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
The project aims to identify women who may be genetically programmed to be more likely to have a fever if they choose epidural (an injection into the back) during labour. By identifying this group of women, we may be able to make their labours more comfortable and less stressful by knowing that they have a higher chance of developing a fever.

Who can participate?
Pregnant women aged over 18 years who request an epidural for labour pain relief

What does the study involve?
Participants will consent to providing a small, single blood sample (as part of the routine blood draw required at the time of the epidural) for genetic analysis. The relationship between one gene that may increase the risk of fever after epidurals and the development of fever and/or prescription of antibiotics plus the outcome of the baby will be recorded.

What are the possible benefits and risks of participating?
There are no direct benefits or risks to participating in this study.

Where is the study run from?
Queen Mary University of London (UK)

When is the study starting and how long is it expected to run for?
From March 2020 to December 2023

Who is funding the study?
The National Institute for Academic Anaesthesia (UK) and the Obstetric Anaesthetists' Association (UK)

Who is the main contact?
Prof Gareth Ackland
g.ackland@qmul.ac.uk

Study website

Contact information

Prof Gareth Ackland
Scientific

Translational Medicine & Therapeutics (218A)
William Harvey Research Institute
Barts and The London School of Medicine and Dentistry
Queen Mary University of London
John Vane Science Centre
Charterhouse Square
London
EC1M 6BQ
United Kingdom

ORCiD logoORCID ID 0000-0003-0565-5164
Phone +44 (0)2078822100
Email g.ackland@qmul.ac.uk

Study information

Study designMendelian randomization study
Primary study designObservational
Secondary study designEpidemiological study
Study setting(s)Hospital
Study typeScreening
Participant information sheet Available from http://qmul.ac.uk/ccpmg/
Scientific titleEPIFEVER-2: Mendelian randomisation study of polymorphisms in interleukin-1 receptor antagonist and epidural-related maternal fever.
Study acronymEPIFEVER-2
Study objectivesPolymorphisms in the interleukin-1 receptor antagonist gene promote fever in labouring women receiving epidural analgesia.
Ethics approval(s)Approved 25/01/2021, London – Bloomsbury Research Ethics Committee (MSE Meeting Rooms, Tottenham Court Road, London, W1T 1BB; +44 (0)207 104 8063; bloomsbury.rec@hra.nhs.uk), ref: 20/LO/1213
Health condition(s) or problem(s) studiedEpidural-related maternal fever in active labour
InterventionWomen are enrolled either in antenatal clinic or on admission to labour ward. A single blood sample is obtained around the time of epidural insertion. Clinical outcomes are collected for the duration of their hospital stay.
Intervention typeOther
Primary outcome measureThe incidence of one or both of the following:
1. Maternal temperature >38°C (triggered by RCOG guidelines for two temperatures >37.5°C) recorded as part of their standard care from patient notes at least 4h after epidural analgesia is commenced
2. Prescription of antibiotics during labour before delivery measured from patient notes before delivery
Secondary outcome measuresClinical outcomes for mother and baby measured from patient notes during their hospital stay
Overall study start date01/03/2020
Completion date31/12/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target number of participants637
Total final enrolment632
Key inclusion criteria1. Aged ≥18 years old
2. Singleton or twin pregnancy
3. Any gestational age
4. Requesting an epidural for labour analgesia
Key exclusion criteria1. Unwilling or unable to give consent
2. Refusal of consent for competent participants
3. Inability to understand written and/ or verbal English
4. Immune/genetic syndromes/mutations
5. Microbiologically proven infection prior to epidural insertion
6. Established pyrexia
7. Intrauterine death
Date of first enrolment28/04/2021
Date of final enrolment31/12/2023

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

Royal London Hospital
Whitechapel Rd
London
E1 1FR
United Kingdom
Homerton Hospital
Homerton Row
London
E9 6SR
United Kingdom
University College Hospital NHS Trust
235 Euston Rd
London
NW1 2BU
United Kingdom
Northern General Hospital
Herries Road
Sheffield
S5 7AU
United Kingdom

Sponsor information

Queen Mary University of London
University/education

Empire House
67-75 New Road
London
E1 1HH
England
United Kingdom

Phone +44 (020) 7882 7275
Email research.governance@qmul.ac.uk
Website http://www.qmul.ac.uk/
ROR logo "ROR" https://ror.org/026zzn846

Funders

Funder type

Research organisation

National Institute for Academic Anaesthesia
Private sector organisation / Universities (academic only)
Alternative name(s)
NIAA
Location
United Kingdom
Obstetric Anaesthetists' Association
Private sector organisation / Associations and societies (private and public)
Alternative name(s)
OAA
Location
United Kingdom

Results and Publications

Intention to publish date31/12/2024
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal. The study protocol and statistical analysis plan will be made publicly accessible on the Queen Mary University of London website http://www.qmul.ac.uk/.
IPD sharing planThe data sharing plans for the current study are unknown and will be made available at a later date.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No
Protocol article 01/05/2022 12/08/2024 Yes No
Results article 14/05/2025 09/06/2025 Yes No

Editorial Notes

12/08/2024: Publication reference and total final enrolment were added.
12/05/2021: Internal review.
29/04/2021: Trial’s existence confirmed by HRA and Health and Care Research Wales (HCRW).